As the 21st century unfolds, rheumatologists will most likely transition from prescribing lupus patients broad immunosuppressants to more targeted treatment approaches. But to make this happen and advance research, the challenges experienced in lupus clinical trial design must be addressed…
Improved Pregnancy Outcomes for Women with SLE
Recent research indicates that previous concerns about mortality associated with pregnancy in women with SLE may no longer be applicable. In the study, researchers found a significant decline in the in-hospital maternal mortality rate of women with SLE and a decrease in their length of non-delivery related hospitalization over the past two decades…
Multiple Interferons, Including IFNB1, May Play a Role in SLE
A recent gene expression analysis found an enriched downstream interferon signature, with predominantly IFNB1 signatures in systemic lupus erythematosus (SLE) patients. The study also found lower expression of all downstream interferon signatures in the kidneys of lupus nephritis patients…
Lupus Pregnancy Outcomes Improved Over the Past 2 Decades
NEW YORK (Reuters Health)—Pregnancy outcomes in women with systemic lupus erythematosus (SLE) have improved markedly over the past two decades, although pregnancy risks remain higher than in women without lupus, according to a trends analysis. “Thirty years ago, most women with SLE were advised to avoid pregnancy because of high risks for maternal and fetal…
Low-Density Granulocytes Activate T Cells in SLE
Recent research indicates that low-density neutrophils, such as low-density granulocytes, exert proinflammatory effects on the T cells of SLE patients. In the study, researchers confirmed SLE patients had a higher prevalence of low-density granulocytes than healthy controls and that these cells appeared to promote a Th1 response…
Insight into Clinical Trials for Lupus
Research into lupus treatments suffered a setback after the failure of anifrolumab in clinical trials. However, during the 2019 ACR State-of-the-Art Clinical Symposium, Richard Furie, MD, outlined the possibilities of multiple new lupus therapies under investigation…
Ixekizumab Promising for Non-Radiographic Axial SpA; Plus FDA Approves Belimumab for Pediatric Lupus
Results from a Phase 3 study showed ixekizumab significantly improved the signs and symptoms of non-radiographic axial spondyloarthritis in patients…
Characterization of Autoreactive B Cells in Patients with SLE & RA
Antibody-secreting cells are important for the pathophysiology of SLE and RA, but researchers have been unable to determine how these cells are activated. A new technique is able to distinguish between naïve autoreactive B cells and established antibody secreting cells…
Anti-Mitochondrial Antibodies & Systemic Lupus Erythematosus
Although antimitochondrial antibodies are present in SLE patients, researchers have has difficulty investigating the phenomenon due to barriers in isolating pure mitochondria. The study describes a technique that allows for such an investigation and provides insight into how the adaptive immune system recognizes mitochondrial organelles…
Metabolic Profiling of SLE
Research examining the metabolic profile of SLE found increased oxidative activity, as well as lower levels of tyrosine and tryptophan, in SLE patients relative to controls, suggesting increased activity of aromatic amino acid decarboxylase. The results suggest metabolomics may have the ability to measure disease severity in SLE…
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- 6
- …
- 12
- Next Page »